Phenobarbital for Agitated Delirium

This trial tests whether phenobarbital can effectively treat agitated delirium in adult ICU patients. Agitated delirium causes confusion and impulsiveness, posing risks to patients and healthcare providers. Researchers aim to determine if phenobarbital can shorten ICU and hospital stays and reduce the need for additional calming medications. Participants will be divided into two groups: one receiving phenobarbital and the other receiving standard antipsychotic medications. The trial seeks adults in the ICU with agitated delirium who are not pregnant, incarcerated, or suffering from severe liver disease. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that phenobarbital is generally well-tolerated by patients. One study demonstrated significant improvement in patients with severe confusion and agitation (agitated delirium) after taking phenobarbital. Specifically, the number of patients experiencing delirium decreased from 100% to 36%, highlighting its effectiveness in managing these symptoms. Importantly, there were no reports of seizures, deaths, or the need for a breathing tube in patients using phenobarbital for alcohol withdrawal, another condition it treats. This suggests it is safe to use, especially since the FDA has already approved phenobarbital for other uses. Researchers closely monitor participants in clinical trials to ensure their safety, addressing any side effects promptly.¹²³⁴⁵

Unlike the standard treatment for agitated delirium, which typically involves antipsychotics, phenobarbital offers a unique approach by leveraging its sedative effects, commonly used in managing alcohol withdrawal. Researchers are excited about phenobarbital because it targets the brain's excitability in a different way, potentially leading to faster calming effects without the side effects associated with antipsychotics. This alternative pathway could provide a more effective and safer option for patients experiencing agitation, offering hope for improved patient outcomes.

Research has shown that phenobarbital can help treat agitated delirium. In one study, the number of people with delirium decreased from 100% to 36% after using phenobarbital. Another study found that phenobarbital shortened ICU stays by facilitating the reduction of other sedative medications. In this trial, participants will receive either a phenobarbital regimen or a conventional antipsychotic-based regimen. Phenobarbital works by boosting a calming chemical in the brain called GABA and lowering glutamate, which can cause excitement. These findings suggest phenobarbital could help manage confusion and agitation in patients with agitated delirium.¹²³⁴⁶